BioTuesdays

ASLAN Pharma gears up for data rich second half

By Len Zehrs ASLAN Pharmaceuticals (NASDAQ:ASLN; TPEx:6497) expects to report topline and interim data in the second half of 2018 from up to four clinical trials with its lead drug candidate, varlitinib, for the...